{"id":"NCT00740051","sponsor":"Boehringer Ingelheim","briefTitle":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","officialTitle":"A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients With Insufficient Glycaemic Control for Whom Metformin Therapy is Inappropriate (Intolerability or Contraindication)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2010-08","completion":null,"firstPosted":"2008-08-22","resultsPosted":"2011-10-26","lastUpdate":"2014-06-27"},"enrollment":227,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Linagliptin","otherNames":[]},{"type":"DRUG","name":"Linagliptin Placebo","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":[]}],"arms":[{"label":"Linagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR"}],"summary":"Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication). The second part of the study looks at the safety of BI 1356 in this patient population with longer term treatment in comparison to a sulfonylurea drug (glimepiride)","primaryOutcome":{"measure":"HbA1c Change From Baseline at Week 18 (Interim Analysis)","timeFrame":"Baseline and week 18","effectByArm":[{"arm":"Placebo","deltaMin":0.14,"sd":0.16},{"arm":"Linagliptin","deltaMin":-0.44,"sd":0.14}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":53,"countries":["United States","Canada","Mexico","Philippines","Romania","Russia","Ukraine"]},"refs":{"pmids":["22974280","22234149"],"seeAlso":["http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.50_Literature.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Hyperglycaemia","Nasopharyngitis","Dizziness","Headache","Upper respiratory tract infection"]}}